VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance

U.S. Markets closed

Vertex Pharmaceuticals Incorporated (VRTX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
89.98+0.93 (+1.04%)
At close: 4:00PM EDT

89.98 0.00 (0.00%)
After hours: 4:44PM EDT

People also watch
ALXNREGNBMRNINCYBIIB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close89.05
Open89.74
Bid87.50 x 100
Ask91.00 x 200
Day's Range89.14 - 90.46
52 Week Range71.46 - 103.73
Volume892,992
Avg. Volume1,619,970
Market Cap22.35B
Beta2.08
PE Ratio (TTM)-195.61
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals8 hours ago

    Concert rebuffed $250M buyout offer from Vertex before CF drug deal

    Lexington-based Concert Pharmaceuticals rebuffed a $250 million buyout offer from Vertex Pharmaceuticals in November before ultimately striking a deal earlier this month to sell a cystic fibrosis drug to the Boston company for $160 million, according to a federal filing. Under the agreement, Vertex is slated to acquire the 69-employee biotech’s cystic fibrosis drug, CTP-656, a reformulation of Vertex’s approved treatment Kalydeco.

  • American City Business Journals7 days ago

    Inside the small Norwood biotech that's making investors swoon

    The top-performing public biotech in Massachusetts over the past year is located in a nondescript brick building with no signage, located along a stretch of highway in Norwood that is better known for its car dealerships than drug developers. Investors in Corbus Pharmaceuticals (CRBP) don’t much seem to mind. The company believes that its anti-inflammatory treatment — initially under the generic name of "resunab" but recently renamed "anabasum" — could treat several rare disorders.

  • Zacks8 days ago

    Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals

    Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals